PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
0.02%
Cash & equivalents yoy growth 0-5% – slight improvement. Peter Lynch would verify if this aligns with revenue trends and if working capital remains healthy.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Cash + STI yoy growth 0-5% – slight gain. Peter Lynch would verify if the firm's operational cash flow sustains normal expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Growth 0-5% – slight uptick. Peter Lynch would see it as generally stable if working capital remains sufficient.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
0-5% yoy – slight growth. Peter Lynch might see it as stable if profitability remains healthy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.90%
Up to 15% yoy – moderate increase. Howard Marks watches if working capital covers this growth.
14.30%
Above 5% yoy – expanding LT debt. Philip Fisher demands clarity on whether growth justifies added leverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.30%
Above 5% yoy – rising long-term liabilities. Philip Fisher wants clarity on new debts or deferrals.
No Data
No Data available this quarter, please select a different quarter.
13.25%
Above 10% yoy – large jump. Philip Fisher demands clarity on whether growth justifies the leverage.
No Data
No Data available this quarter, please select a different quarter.
-2.27%
Declining retained earnings signals net losses or large dividends. Seth Klarman would investigate the sustainability of dividend policy.
No Data
No Data available this quarter, please select a different quarter.
41.19%
Above 10% yoy – bigger jump. Philip Fisher demands clarity on unusual equity expansions.
-16.23%
Declining stockholders equity may signal losses or large distributions. Seth Klarman would investigate the underlying causes and sustainability.
0.02%
0-3% yoy – small growth. Peter Lynch wonders if expansions are limited or offset by divestitures.
No Data
No Data available this quarter, please select a different quarter.
14.30%
Above 5% yoy – debt expansion. Philip Fisher demands clarity on whether new debt is productive or just adding leverage.
17.98%
Above 5% yoy – net debt expansion. Philip Fisher demands clarity on the reason for higher leverage vs. cash.